The Food and Drug Administration has granted accelerated approval to Lartruvo (olaratumab) injection with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS).
Daratumumab with bortezomib and dexamethasone is associated with longer progression-free survival in patients with relapsed or relapsed and refractory multiple myeloma, according to a study published in the August 25 issue of the New England Journal of Medicine.
The Food and Drug Administration (FDA) has approved supplemental Biologics License Applications (sBLA) for Amgen’s Prolia (denosumab) and Xgeva (denosumab).
Daratumumab (Darzalex), a recently approved immunotherapy drug for multiple myeloma, can provide better benefits if patients receive it earlier in their treatment, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held in Chicago.
Older patients with soft-tissue sarcomas may benefit more from radiation therapy after surgery than younger patients do, according to research published in Anticancer Research.
In a case report published online February 28 in the Journal of Clinical Pharmacy and Therapeutics, researchers document non-HIV-associated Kaposi sarcoma in a male patient with myasthenia gravis and metastatic melanoma treated with the BRAF inhibitor dabrafenib.
Overall rates of cancer and cancer mortality in the United States continue to decline, according to the Annual Report to the Nation on the Status of Cancer.
The Food and Drug Administration (FDA) has approved Halaven (eribulin mesylate; Eisai) for the treatment of unresectable or metastatic liposarcoma in patients who have received prior chemotherapy containing an anthracycline.